In Summary
CRISPR Therapeutics is at week 4 of a sell signal with strength down to 36 out of 100: bearish pressure is weak, the picture is deteriorating but without acceleration. The confirmation week closed bullish, an unfavorable signal for anyone holding short positions. The quality band indicates trading is not recommended for new entries.
Sell signal in observation
·3rd week from start
·US stocks
·T2
IQS Phase
59
ordinary
Signal Strength
36
medium · weak
Sizing
REDUCED
Ranking
#15 / 80
US stocks sell signals
restricted Platinum content